The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia
PHASE2CompletedINTERVENTIONAL
Enrollment
27
Participants
Timeline
Start Date
November 1, 2017
Primary Completion Date
December 31, 2020
Study Completion Date
December 31, 2020
Conditions
ESRDHyperkalemiaEnd Stage Renal Disease
Interventions
DRUG
Patiromer
Patiromer will be orally self-administered by participants.
Trial Locations (1)
20037
DaVita K Street, Washington D.C.
All Listed Sponsors
lead
Dominic Raj
OTHER
NCT03326583 - The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia | Biotech Hunter | Biotech Hunter